Drug Trial Radar · NCT06350630
Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
334
Planned (sponsor's estimate)
Start
Jun 26, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public health issue. Its pathophysiology seems to be triggered by mucosal immunity abnormalities leading to the systemic misaddressing of mucosal IgA, generation of circulating immunoglobulin A1 (IgA1) immune complexes finally deposited in renal glomeruli leading to renal tissue inflammation and scarring processes. Among this pathogeny, innate immunity is involved at several steps, including mucosal immunity. In this regard, hydroxychloroquine has been shown to generate a global anti-inflammatory effect, particularly through its action on Toll like receptors and dendritic cells. This drug is well tolerated, widely used for other auto-immune diseases (e.g. Systemic Lupus Erythematosus) and very low priced. One randomized controlled study conducted in China has recently shown a significant drop in proteinuria of IgA nephropathy patients treated with hydroxychloroquine (-48.4%) compared to the placebo group (+10.0%), after a quite short-term follow-up (6 months) and a moderate statistical power (30 patients in each group). Considering (i) the potential mechanism of therapeutic effect on this disease, (ii) the well documented safety profile of the drug for rheumatologic indications and posologies, and its low cost (iii) its efficacy in reducing proteinuria in IgA nephropathy patients in a preliminary Chinese randomized control study, the investigators aim in this study at establishing the beneficial impact of hydroxychloroquine on IgA nephropathy in a double blind randomized controlled trial on a Caucasian French population with harder outcomes and a longer follow-up compared to the Chinese preliminary study.
Conditions
- IgA Nephropathy
Interventions
Hydroxychloroquine Oral TabletDrug
Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years
Placebo oral tabletDrug
placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute difference in estimate Glomerular Filtration Rate (GFR) between hydroxychloroquine group and control group evolutionTime frame: 3 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
CHU Gabriel Montpied
Clermont-Ferrand, France · Recruiting
Hospices Civils de Lyon
Lyon, France · Recruiting
AP-HM Hôpital de la Conception
Marseille, France · Recruiting
Chr Metz Thionville Hopital Mercy
Metz, France · Recruiting
APHP Hôpital Bichat
Paris, France · Recruiting
APHP Hôpital de Tenon
Paris, France · Recruiting
CHU Lyon Sud
Pierre-Bénite, France · Recruiting
CHU de Saint-Etienne
Saint-Etienne, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.